ASXAppendix 4G and Corporate Governance Statement
other announcement
Cann Group (CAN) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineHas Cann Group Reset Itself for an Export Push (ASX:CAN)?
Highlights Annual report due as the Mildura grower emerges from a debt reset Global scramble for certified cannabis capacity frames the story Market value still sits well below reported net assets Cann Group (ASX:CAN) is set to lodge its annual report in the coming days as the September deadline for June balance-date companies arrives, putting fresh attention on a Mildura cannabis grower that has swapped a crippling bank debt for a leaner balance sheet and is now chasing export orders. Why th...
Why Could Cann Group (ASX:CAN) Matter for Cannabis?
Highlights Cann Group (ASX:CAN) is a licensed Australian cultivator and manufacturer of medicinal cannabis. The company operates cultivation and manufacturing facilities in Victoria. Its performance is closely tied to domestic patient demand and regulatory settings. Among the licensed players shaping Australia's medicinal cannabis landscape, Cann Group (ASX:CAN) remains a name worth tracking closely. Operating cultivation and manufacturing facilities in Victoria, the company sits firmly withi...
Google NewsWhy Could Cann Group (ASX:CAN) Matter for Cannabis Stocks? - Kalkine Media
Why Could Cann Group (ASX:CAN) Matter for Cannabis Stocks? Kalkine Media
Why Could Cann Group (ASX:CAN) Be Worth Watching Today?
Highlights Cann Group (ASX:CAN) is a licensed Australian cultivator and manufacturer of medicinal cannabis. The company operates cultivation and manufacturing facilities in Victoria. Its performance is closely tied to domestic patient demand and regulatory settings. Among the licensed players shaping Australia's medicinal cannabis landscape, Cann Group (ASX:CAN) remains a name worth tracking closely. Operating cultivation and manufacturing facilities in Victoria, the company sits firmly withi...
Are Cann Group (ASX:CAN) Export Doors Opening At Mildura?
Highlights A manufacturing licence for therapeutic goods at the Victorian facility completed the suite of permits the site required. [ASX 300] The accreditation allows production of active pharmaceutical ingredients and capsules, alongside approved laboratory work. Material made at the site can reach patients through domestic access pathways as well as export markets. Cann Group, the Victorian medicinal cannabis producer trading as (ASX:CAN), has secured a good manufacturing practice licence ...
Cann Group (ASX:CAN): Can exports reinforce?
Highlights Cann Group has a fresh disclosure linked to cash discipline, manufacturing use and export execution. The Mildura cultivation facility and export channels remain central to the operating assessment. Execution, cash discipline and disclosure continuity remain the clearest markers. [All Ordinaries] Cann Group (ASX:CAN) is back in focus after fresh annual results described a reset balance sheet, lower operating costs and export activity. The timely update directs attention to the Mildu...
Sabalenka interrupts US Open match over cannabis smell
Aryna Sabalenka encounters a distracting odour during her US Open third-round victory over Kamilla Rakhimova in New York.
What Could Cann (ASX:CAN) Mean for Cannabis Stocks?
Highlights Cann Group runs cultivation and manufacturing capacity in northern Victoria aimed at both local and export demand. Its consumer facing capsule range sits alongside a broader medicinal product portfolio. Fresh shares were quoted during the year as convertible securities were exercised. Cann Group (ASX:CAN) is drawing a sharper market lens as sector conditions and company execution intersect across Australian equities. Cann Group (ASX:CAN) is working to fill the cultivation and manuf...
Why Could Cann Group (ASX:CAN) Shift the Cannabis Story?
Highlights The cultivator finished the financial year with its best cash performance to date and a second cash flow positive quarter. A debt restructure and equity raise earlier in the period reset the balance sheet after a difficult stretch. Domestic oversupply and falling product prices remain the defining pressure across the Australian medicinal cannabis market. Cann Group (ASX:CAN) is entering the market conversation from a different angle than many peers: the newest update puts execution...
Cann Group (ASX:CAN) Earnings Spotlight: What Investors Are Watching on 19 August
Highlights On 18 August, the [S&P/ASX 200] finished at, down points, while the [All Ordinaries] closed at. Cann Group (ASX:CAN) is the primary company lens, while Little Green Pharma (ASX:LGP), Incannex Healthcare (ASX:IHL), ECS Botanics (ASX:ECS) provide category context. The article focuses on regulatory execution, funding needs and commercial traction without using directional investment recommendations. The central question for cannabis stocks is no longer simply whether the macro bac...
Cann Group (ASX:CAN) Sector Pulse: What Could Shape the Next Move on 19 August
Highlights Healthcare was the standout sector on 18 August: CSL rose sharply after its FY26 result, while Cochlear and Pro Medicus also drew strong market reactions. Cann Group (ASX:CAN) is the primary company lens, while Little Green Pharma (ASX:LGP), Renascor Resources (ASX:RNU), BrainChip Holdings (ASX:BRN) provide category context. The article focuses on funding discipline, liquidity and milestone quality in lower-priced shares without using directional investment recommendations. Lower-p...
What Makes Cann Group (ASX:CAN) Stand Out in Cannabis?
Highlights Cann Group is viewed through patient demand, product mix and distribution reach, keeping the discussion anchored to company-specific operating evidence. The Cannabis Stocks lens is used only as context; the article separates Cann Group's business model from broader sector shorthand. Fresh disclosures around regulatory execution, cultivation efficiency and commercial scale are the most useful checkpoints for judging how the narrative is evolving. The Australian sharemarket is giving...
Cann Group (ASX:CAN) Widens Pharmacy Distribution
Highlights A national pharmacy chain arrangement extends reach beyond specialist dispensing channels. The Mildura facility remains the largest single production asset the company operates. Utilisation rather than capacity is now the determining variable for unit economics. Cann Group (ASX:CAN), one of the earliest licensed Australian medicinal cannabis cultivators and the operator of a large certified manufacturing facility at Mildura in Victoria, has kept market attention on its distribution...
Cannabis Stocks Are Heating Up: Key Players to Watch as Market Momentum Builds
Highlights Little Green Pharma Ltd (ASX:LGP), Cann Group Limited (ASX:CAN), Botanix Pharmaceuticals Limited (ASX:BOT) are among the ASX names in focus as investors assess the sector outlook. Company-specific performance remains important, with investors watching operating delivery, financial strength and sector-relevant milestones across LGP, CAN and BOT. Business execution, balance-sheet discipline and valuation remain important alongside broader market themes. Australias share market offers...
Why Is Cann Group (ASX:CAN) Back in Focus?
Highlights Cann Group is in focus after a fresh company disclosure added new context to the public record. The cannabis stocks lens centres on regulated market access, product mix, distribution reach and cash discipline. The broader Australian market backdrop remains important when reading company-specific developments. Australian shares are being assessed against a shifting mix of company updates, sector conditions and global market signals, making fresh disclosures especially important for ...
Cann Group sets the tone after operating update
Highlights Cann Group is drawing attention today around operating update. The update gives the sector a fresh company-specific news hook. Execution and wider market conditions remain central to the next read-through. Cann Group (ASX:CAN) is in focus today as the Australian market weighs operating update, putting the companys latest operational narrative at the centre of a busy local trading session. Why the update matters now The immediate reaction matters less than the reason the development...
Cann Group (ASX:CAN): Why Does Production And Sales Matter?
Highlights Cann Group's August reporting-season setup puts production and sales at the centre of the immediate market discussion. Australian cannabis stocks conditions keep Cann Group sensitive to demand, costs and liquidity through the reporting cycle. For Cann Group, the test is whether liquidity can support execution and financial flexibility through the next cycle. Australian shares enter the session with reporting season sharpening attention on company-specific evidence, while broader ra...
Why Cann Group's First-Mover Advantage Strengthens as Medical Cannabis Market Accelerates on ASX Is in Focus (ASX:CAN)?
Highlights Cann Group (ASX:CAN), Cann Group Limited (ASX:CAN) remains in focus as medical cannabis development and operational delivery continue shaping sector attention. Patient access, regulation and product quality remain central considerations as Australian companies respond to evolving market conditions. Balance sheet management, strategic discipline and consistent execution continue influencing the broader business outlook. Australia's cannabis stocks landscape remains closely watched a...
Cann Group (ASX:CAN): Can Operating Delivery Change the Story?
Highlights Cann Group enters the reporting period with operating cash use and customer demand central to the next company disclosure and the wider market debate. The Penny Stocks backdrop is testing liquidity, milestones and balance-sheet runway as rates, demand and capital discipline shape market interpretation. A comparison with ECS Botanics clarifies differences in scale, operating exposure, funding needs and sensitivity to external conditions. Local equities move into the current reporting...
AusCann Group Holdings (ASX:AC8): Is Margin Discipline the Key Signal?
Highlights AusCann Group Holdings enters the reporting period with strategy, liquidity and disclosure milestones central to the next company disclosure and the wider market debate. The Cannabis Stocks backdrop is testing regulation, cash runway and product economics as rates, demand and capital discipline shape market interpretation. A comparison with Little Green Pharma clarifies differences in scale, operating exposure, funding needs and sensitivity to external conditions. The Australian sha...
Cann Group (ASX:CAN): Why Is Reporting Season in Focus?
Highlights Cann Group enters the reporting period with cash use and production economics central to the next company disclosure and the wider market debate. The Cannabis Stocks backdrop is testing regulation, cash runway and product economics as rates, demand and capital discipline shape market interpretation. A comparison with Little Green Pharma clarifies differences in scale, operating exposure, funding needs and sensitivity to external conditions. The domestic share market begins the curre...
Why Is the Market Watching Cann Group (ASX:CAN)?
Highlights Cann Group closes the financial year with its strongest cash performance to date, reporting a second straight quarter of positive operating cash flow. Customer receipts strengthen as flower supply agreements and export orders continue to build across the group's cultivation base. Management flags scope for further consolidation moves across the medicinal cannabis sector as smaller operators weigh their options. Cann Group (ASX:CAN), the Melbourne-based medicinal cannabis cultivator...
Why Is Cann Group (ASX:CAN) Still In Reset Mode?
Cann Group is being read through balance sheet repair and product execution as cannabis stocks regain attention The latest ASX mood blends local inflation relief with offshore caution Botanix adds a peer reference that keeps the category story grounded Local readers are balancing rate expectations with commodity moves, balance sheet strength and sector breadth, leaving Cann Group in a sharper editorial frame for Australian market readers. Botanix Pharmaceuticals (ASX:BOT), dermatology company c...
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Could Cann (ASX:CAN) Change the Cannabis Stocks Narrative?
Highlights Cann sits inside a sharper regulated cannabis debate after thin sector news pushing attention back to balance sheets and product channels. Canns position in the sector breadth shift inside Cannabis Stocks rewards cleaner balance sheets, steadier revenue and credible execution. Cannabis Stocks around Cann remain tied to local rates, offshore leads and company-specific operating evidence. The Australian share market moved into today's session with a cleaner risk tone, and ECS Botanic...
Cann Group (ASX:CAN): One Cannabis Label, Two Very Different Paths
Highlights One producer expanded its share base to fund cultivation and manufacturing ambitions. Another is pursuing clinical development of a cannabis-derived compound for neurological conditions. The contrast highlights the breadth of strategies across the Australian cannabis space. Two Australian names sit at opposite ends of the cannabis spectrum, one focused on large-scale cultivation and the other on clinical drug development, illustrating how varied the sector has become. Cann Group (A...
Can local cannabis cultivation withstand cheap imports?
Highlights Cann Group kept attention as an early Australian cultivator drawing on fresh capital. Home-grown cultivation faced keen competition from imported product. Domestic manufacturing capability shaped the group's longer-term story. Cann Group (ASX:CAN), among the earliest movers in Australia's licensed medicinal cannabis industry, drew attention today as it looked to fresh capital to support its operations while the domestic cultivation landscape grows more competitive. As a home-grown pr...
Why Is Cann Group (ASX:CAN) Back in the Cannabis Debate?
Highlights Cann Group is drawing attention as cultivation efficiency and operating discipline return to the centre of the cannabis discussion. Cost control, cash conversion and evidence of patient demand are carrying more weight than broad sector enthusiasm. Currency movements, funding conditions and selective Australian market sentiment are sharpening scrutiny of commercial delivery. The Australian share market is moving through a cautious session as higher energy costs, geopolitical unc...
Cann Group (ASX:CAN) Recalibrates as Cannabis Funding Gets Harder
Highlights Capital raising remains a defining feature of the Australian cannabis sector's listed companies. Manufacturing scale at accredited facilities is proving more valuable than raw cultivation footprint. The path from licence to sustainable revenue is longer than the sector once assumed. Cann Group (ASX:CAN), one of the earliest movers in Australia's medicinal cannabis industry and the operator of an accredited manufacturing facility at Mildura in Victoria, continues to navigate the secto...
What Is CAN Revealing About Cannabis Stocks Right Now?
Highlights Cann Group is attracting renewed attention as operating improvements become a key market focus. Market participants are placing greater emphasis on execution, cash generation and business discipline. The evolving outlook for Cannabis Stocks is being shaped by operational resilience rather than sector optimism. CAN remains in focus as operational improvements, business discipline and sector resilience shape confidence across Australia's medicinal cannabis industry and broader Ca...
Cann Group (ASX:CAN) Inks UK and EU Supply Deals in Fresh Export Push
Highlights Cann Group has signed two agreements to supply medicinal cannabis oil and dried flower products into Britain and the European Union. The company has also sought quotation of a fresh tranche of shares, part of ongoing balance-sheet housekeeping after a demanding few years. Offshore demand is fast becoming the lifeline for Australian cultivators squeezed by intense price competition at home. Cann Group (ASX:CAN), one of the first companies licensed to cultiva...
Why do Cann Group (ASX:CAN) shares keep swinging on the ASX?
Highlights Cann Group shares remain volatile as the medicinal cannabis cultivator works through a challenging earnings backdrop. The Mildura-based grower has narrowed its losses even as revenue softened over its past reporting period. The stock's swings highlight the broader risk and reward dynamic still facing smaller ASX cannabis cultivators. Shares in Cann Group (ASX:CAN) have continued to swing sharply as the Mildura-based medicinal cannabis cultivator navigates a...
Cann (ASX:CAN) Lists New Shares as ASX Cannabis Sector Faces Revenue Reckoning
Highlights Cann Group applied for quotation of newly issued ordinary shares as part of its ongoing capital management. Australia's medicinal cannabis sector is placing greater emphasis on revenue generation and commercial execution. Licensed producers are increasingly being assessed on financial performance rather than sector optimism alone. Australia's share market continues to reward companies that demonstrate commercial progress over market excitement, and that tren...
StockheadAI scanners and facial recognition set to slash airport queues
This is how advanced tech, including AI, is making it faster to get through security and stopping our bags from ... Read More The post AI scanners and facial recognition set to slash airport queues appeared first on Stockhead.
Cann (ASX:CAN) and ECS Botanics Take Centre Stage as Cannabis Stocks Face a New Reality
Highlights Cannabis stocks are moving into a more selective market phase where operational progress is attracting greater attention than broad sector enthusiasm. Cann Group (ASX:CAN) and ECS Botanics (ASX:ECS) have become important reference points as the Australian medicinal cannabis sector matures. Market participants are increasingly comparing funding discipline, business execution and regulatory developments across the sector. Australia's share market has ...
Cann (ASX:CAN): Why Manufacturing Quality Is Putting Cannabis Stocks Back in Focus
Highlights • Manufacturing quality and regulatory discipline are reshaping how the Australian market views the cannabis sector. • Cann Group (ASX:CAN) and Vitura Health (ASX:VIT) highlight how different business models are influencing the category narrative. • The focus has shifted from broad sector enthusiasm to execution, operational resilience and regulated product confidence. Australia's share market continues to navigate a...
Cann Group (ASX:CAN): Why Is Cannabis Access The Key Test?
Highlights ASX cannabis stocks are being assessed through regulated access, channel strength and compliance quality. Cann Group and Vitura Health show why company-specific proof matters more than broad sector labels. Market attention is shifting toward execution discipline, funding clarity and commercial pathways. ASX cannabis stocks are being assessed through regulated access, compliance, c...
Cann Group (ASX:CAN): Can This Cannabis Stock Rebuild Investor Confidence? - Kalkine
Cann Group (ASX:CAN): Can This Cannabis Stock Rebuild Investor Confidence? Kalkine
Cann Group (ASX:CAN): How TGA Rules Are Reshaping Australia's Medicinal Cannabis Market
Highlights Australia's medicinal cannabis industry continues to expand under a tightly regulated Therapeutic Goods Administration framework. The Special Access Scheme has supported rising prescription demand, benefiting compliant licensed producers. Recreational cannabis remains illegal federally, keeping the commercial focus on medical products and regulated export markets. Australia's medicinal cannabis sector is evolving within one of the world's most st...
Cann Group (ASX:CAN) kills the Obsidian note early and lifts the dilution overhang - Stocks Down Under
Cann Group (ASX:CAN) kills the Obsidian note early and lifts the dilution overhang Stocks Down Under
Why Is Cann Group (ASX:CAN) Expanding as Cannabis Funding Evolves?
Highlights Cann Group is advancing production capability through continued investment in its Mildura manufacturing operations. The medicinal cannabis industry remains dependent on capital as businesses expand commercial operations. Manufacturing quality and operational execution are becoming key differentiators across Australia's cannabis sector. Cann Group continues expanding production capabil...
Why Are Cann Group (ASX:CAN) and Little Green Pharma (ASX:LGP) Back in Focus?
Highlights ASX cannabis licensed producers are shifting focus toward measurable commercial performance. Cann Group (ASX:CAN) and Little Green Pharma (ASX:LGP) highlight contrasting business models. The sector is moving from approvals-driven narratives to revenue-driven outcomes. ASX cannabis producers are shifting from licensing narratives to commercial performance, with Cann Group and Little Gr...
CAN (ASX:CAN): Why Cash Runway Is Becoming the Real Penny Stock Test
Highlights Cash runway is becoming a major focus as markets place greater emphasis on funding resilience and operational execution. Cann Group, ECS Botanics and Neurotech International are highlighting how company-specific developments are shaping sentiment across penny stocks. Market participants are increasingly rewarding businesses that demonstrate financial discipline and credible progress. Australia’s small-cap market remains one of the most closely wat...
Cann Group (ASX:CAN)- Why Are Cannabis Stocks Now Chasing Proof Over Hype?
Highlights Revenue generation and clinical evidence are becoming the key differentiators across Australia's cannabis sector. Stronger regulatory oversight is encouraging greater focus on quality, compliance and commercial execution. The medical cannabis industry continues to evolve as businesses prioritise sustainable growth over speculation. Australia's medical cannabis sector is entering a new...
Cann Group (ASX:CAN): Export Quality Race Reshaping Cannabis Stocks
Highlights Export-quality medicinal cannabis is emerging as a key differentiator across the Australian cannabis sector as market participants focus on execution over narrative. Cann Group (ASX:CAN), Little Green Pharma (ASX:LGP), ECS Botanics Holdings (ASX:ECS) and Zelira Therapeutics (ASX:ZLD) highlight different approaches to scale, production quality and commercial delivery. European GMP standards are increasingly shaping how the market evaluates premium cannabis suppliers and long-term sect...
Cann Group (ASX:CAN): Why Cashflow Is Becoming the Real Cannabis Test
Highlights Patient access and cash-flow quality are becoming the key measures for evaluating Australian cannabis companies. Cann Group, Little Green Pharma and ECS Botanics Holdings highlight different approaches to scale, margins and operational execution. Market attention is increasingly focused on whether industry growth can translate into stronger unit economics and financial discipline. Australia's share market is navigating a period where proof matters more than promise. As traders asse...
Is Cann Group (ASX:CAN) Shifting Gear After New Share Quotation?
Highlights Cann Group (ASX:CAN) has added a new batch of ordinary shares to its ASX-quoted structure. The issuance stems from conversion-linked instruments rather than a fresh capital raising. Medicinal cannabis sector continues to mature under tighter regulatory and commercial discipline. Cann Group has expanded its ASX-listed share base through conversion-linked issuance, reflecting normal capital structure evolution in the medicinal cannabis sector. Australia’s healthcare-linke...
CAN (ASX:CAN): Penny Stocks Face a Funding Clock
Highlights ASX penny stocks are being assessed through cash runway, liquidity and disciplined news flow. Cann Group (ASX:CAN), ECS Botanics (ASX:ECS) and Little Green Pharma (ASX:LGP) sit near the centre of the current watchlist. The key test is whether funding discipline can support confidence beyond a short trading burst. ASX penny stocks are being filtered through funding risk, cash runway, trading liquidity and catalyst quality as selective market conditions place speculative names under ...
CAN (ASX:CAN): Smallcap Risk Filter Returns After Flat ASX
Highlights ASX smallcap stocks are being filtered through capital runway, liquidity and execution after a flat market session. Cann Group (ASX:CAN), ECS Botanics (ASX:ECS) and Baby Bunting Group (ASX:BBN) sit near the centre of the current smallcap watchlist. Risk appetite remains alive, but balance-sheet strength and credible catalysts are now doing more of the heavy lifting. ASX smallcap stocks are facing a sharper risk filter as market attention shifts towards liquidity, capital runway, ca...
Medicinal Cannabis Shares Meet A Stricter Export Check
Highlights Cannabis stocks are being assessed through export quality, medicinal access and revenue discipline. ECS Botanics and Cann Group bring a company-level lens to the local medicinal cannabis theme. The sector remains niche, with market attention focused on product standards, funding strength and offshore channels. Cannabis stocks face a sharper export quality test as medicinal access, product standards, revenue durability and funding discipline become central to the latest ASX se...